I get that.
But I wonder how many other biotech or medtech stocks you value that way?
The current studies will extend the treatment options to investigational radiology and to folfirinox chemo respectively. They will not only expand the label significantly but potentially lead to government reimbursement.
This is my problem: the valuation of a bunch of companies with non-approved (and maybe never approvable) technologies is way higher than ours.
So, if you have other biotechs or medtechs why don;t you apply the same reasoning to them?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.070(5.69%) |
Mkt cap ! $16.49M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.25 | $1.11 | $72.36K | 60.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9286 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 412 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |